HKSDS Program
Hong Kong, 000000
NCT Number: NCT04868175
This is a prospective study of IOP in Intravitreal injections to evaluate:
1. IOP effect of intravitreal injection 2. IOP response to prophylactic beta blocker or Prostaglandin vs control (Hypromellose) over multiple time periods 3. IOP response in correlation to number of injections, IOL, type of anti VEGF, co morbidities
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Not applicable
Hong Kong, 000000
Study design: A prospective study Sample size: 60 patients (180 readings) Recruitment: Patients will be recruited at the intravitreal injection clinic in Grantham Hospital.
Randomization:
Group 1: control (hypromellose), then Timolol, then Travatan Group 2: Timolol, then Travatan, Hypromellose Group 3: Travatan, then Hypromellose, Timolol
There are three groups of different treatments. Patients recruited will undergone all three groups of treatments. During the first injection visit, patients will be randomized (by envelope method upon recruitment) to start with one of the three groups by envelope method. Treatment given to each group according to randomization in the first visit, then rotated to second and third group at two subsequent injections accordingly.
Injection doctors masked to treatments given.
Study visits:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
Placebo eye drop, lubricant
Time frame: From baseline to 30 minutes after injection
IOP in mmHg
Time frame: From baseline to 30 minutes after injection
IOP in mmHg
Time frame: From baseline to 30 minutes after injection
IOP in mmHg
Time frame: 1 week post injection
presence of inflammation
The University of Hong Kong
Other
The Effects of Topical Beta Blocker and Prostaglandin on Interval Intraocular Pressure in Intravitreal Injection - a Randomised Controlled Prospective Study
Acronym: IIII
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07604428
Apnea, Eye Diseases
Olomouc, Czechia
View Trial DetailsNCT06689696
Eye Diseases, GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Fullerton, California, United States
View Trial DetailsNCT03057301
Eye Diseases, Glaucoma
Edinburgh, Midlothian, United Kingdom
View Trial DetailsNCT04698876
Behavior, Eye Diseases
Dortmund, Germany
View Trial Details